An official website of the United States government
Government Funding Lapse Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.
The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.
Updates regarding government operating status and resumption of normal operations can be found at opm.gov.
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Trial Status: active
This is a first-in-human, open-label, dose escalation and expansion study of UCART22
administered intravenously to patients with relapsed or refractory B-cell acute
Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and
clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and
Recommended Phase 2 Dose (RP2D)
Inclusion Criteria
Inclusion Criteria:
- B-ALL blast cells expressing CD22
- Diagnosed with R/R B-ALL
- Prior therapy must include at least one standard chemotherapy regimen and at least
one salvage regimen
Exclusion Criteria:
-Prior cellular therapy or investigational cellular or gene therapy within 90 days prior
to enrollment
Additional locations may be listed on ClinicalTrials.gov for NCT04150497.
